Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galunisertib in Myelodysplastic Syndromes
NCT02008318Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2014
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of galunisertib in myelodysplastic syndrome (MDS), sponsored by Eli Lilly and Company. Started Mar 2014; status: completed.
02
Drugs
galunisertib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02008318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02008318.